After verifying results in 1375 cases and analyzing 1804 stage II/III CRC cases from clinical trials, a lower recurrence risk corresponded with increased CD8+ density (HR = 0.92, P-value = 0.0036) was identified [98]. This evidence concerns the gene CD8A and colorectal carcinoma.